SOURCE: Radient Pharmaceuticals Corporation
Spanish Language Site Supports Product Commercialization and Serves as Critical Communication Tool in Spanish-Speaking Markets
TUSTIN, CA–(Marketwire – July 29, 2010) – US-based Radient Pharmaceuticals Corporation (
As RPC’s distribution partner for Central America, South America, Mexico and the Caribbean, Perceptive Imagineering is responsible for commercialization efforts, including product registration, marketing, sales and support for the licensing and distribution of Onko?Sure in these regions. The newly launched site is a companion to RPC’s corporate websites: Radient-Pharma.com and Onko-Sure, and delivers detailed information on Radient Pharmaceuticals, Onko-Sure and Onko-Sure product sales and distribution in Latin American and surrounding regions. This website also includes a valuable FAQ section with answers to the most commonly asked questions about Onko-Sure, scientific literature regarding the test, basic information about cancer and cancer testing in Latin America, RPC’s CLIA laboratory testing resources and general information on cancer screening, testing and treatment.
According to Douglas MacLallan, Chairman and CEO of Radient Pharmaceuticals, “The launch of this new site supports our commercialization efforts in Latin America and serves as a critical communication tool in this geographical region. The site is an invaluable resource to educate our key Latin American audiences, which include cancer patients, the medical and healthcare community at large, existing and prospective investors, partners and suppliers on the Company and Onko-Sure and Onko-Sure’s merits as a non-invasive, simple blood test for cancer screening and testing.”
Perceptive specializes in assisting US medical companies in bringing their products into Latin America. Perceptive Imagineering, LLC is led Dr. Nancy Alvarez, and, under her leadership, her company is well?suited to lead the licensing, distribution and commercialization efforts for RPC’s Onko?Sure cancer test in this market.
Onko-Sure IVD cancer test is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection, screening, and monitoring of various types of cancer. The test enables physicians and healthcare professionals to effectively monitor and/or detect certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure™ is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer detection and monitoring test.
About Radient Pharma:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is a US-based pharmaceutical company specializing in the research, development and sales of In Vitro Diagnostic Cancer tests. The Company’s focus is on the discovery, development & commercialization of unique high?value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve outcomes for patients. Our Onko?Sure™ IVD cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. For additional information on RPC and its portfolio of cancer products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.
Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
AMDL Contact:
Kristine Szarkowitz
Director-Investor Relations
Email Contact
(Tel: ) 206.310.5323
Click here to see all recent news from this company